

Please try another search
Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.
Name | Age | Since | Title |
---|---|---|---|
Lars G. Ekman | 71 | 2005 | Independent Chairman |
Gene G. Kinney | 52 | 2012 | President, CEO & Director |
Paula K. Cobb | 48 | 2019 | Independent Director |
Shane Martin Cooke | 59 | 2012 | Independent Director |
Richard T. Collier | 67 | 2012 | Independent Director |
Dennis J. Selkoe | 78 | 2013 | Independent Director |
Oleg Nodelman | 45 | 2019 | Independent Director |
Karl Anders Olof Härfstrand | 66 | 2015 | Independent Director |
Sanjiv K. Patel | 48 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review